Thursday September 27th

08.30 – 09.30 Registration and welcome coffee

09.30 – 10.00 Greetings from Institutions

Enrico Giunchiglia – Pro-Rector of the University of Genoa
Gianluigi Mancardi – President of Italian Society of Neurology
Sonia Viale – Councilor for Health of Liguria region

Opening remarks

Massimo Mauro – AISLA President
Alberto Fontana – AriSLA Foundation President
Giambattista Bonanno – MND Representative

2nd MND meeting and 7th AriSLA meeting

10.00 – 10.15 In memoriam of Maria Teresa Carrì

Caterina Bendotti

10.15 -11.15 Opening lecture

Presented by Piera Pasinelli
Pamela Shaw
A Translational Neuroscience approach to improve outcomes for ALS/MND: the Journey so far and Future Prospects


Session 1: MN vulnerability (I): Protein quality control and stress response

Chairs: Valentina Bonetto and Simon Alberti

11.15 – 11.45 Simon Alberti

Aberrant phase transitions: a cause of many age-related neurodegenerative disorders?

11.45 – 12.15 Serena Carra

AriSLA Full Grant Project, Call 2014
GRANULOPATHY – VCP and autophagolysosomal pathway: guardians of proteostasis and stress granule dynamics. Unraveling their implications in ALS

12.15 – 12.30 Alessandro Rosa

AriSLA Pilot Grant Project, Call 2016
StressFUS – Impairment of the stress response by mutant FUS in iPSC-derived human ALS motoneurons

12.30 – 12.45 Maria Elena Cicardi

TDP25 aggregation in motor neuron and muscle cells is rescued by chaperone overexpression.

12.45 – 13.00 Francesco Bemporad

The aggregation propensity of human profilin-1 correlates with the stability of an aggregation-prone partially folded state

13.00 – 14.30 Lunch

13.30 – 14.30 Poster session: MND meeting, discussion P1-P15

AriSLA posters “2017 AriSLA Call” (P42-47)


Session 2: MN vulnerability (II): Nucleic Acid Dysfunction

Chairs: Emanuele Buratti e Adriano Chiò

14.30 – 15.00 Fabian Feiguin

AriSLA Full Grant Project, Call 2014
CHRONOS – Chronic and Sporadic Mechanisms of TDP-43 Dysfunction

15.00 – 15.30 Irene Bozzoni

AriSLA Full Grant Project, Call 2014
ARCI – RNA circuitries in Amyotrophic Lateral Sclerosis pathogenesis

15.30 – 15.45 Lara Marrone

Modelling fus-amyotrophic lateral sclerosis using gene-edited isogenic ipsc reporter lines

15.45 – 16.00 Paolo Paganetti

New cellular functions for microtubule-associated Tau, a protein involved in the FTD-ALS spectrum of diseases

16.00 – 16.30 Coffee Break


Session 3: ALS-FTD: new insights

Chairs: Valeria Crippa e Davide Trotti

16.30 – 17.00 Davide Trotti

Triggers of RAN translation and evidence of C9orf72-linked dipeptide repeat proteins propagation

17.00 – 17.30 Dieter Edbauer

A closer look at poly-GA pathology in C9orf72 ALS

17.30 – 17.45 Veronica Castelnovo

Progression of cognitive and behavioral disturbances in motor neuron disease

17.45 – 18.00 Cristina Moglia

Lifetime Sport Practice and Brain Metabolism in Amyotrophic Lateral Sclerosis: a 18F-FDG-PET study

18.00 – 19.00 Poster session: MND Meeting, discussion P16-P27

AriSLA Best Poster Prize evaluation P48-P57

19.00 – 20.00 Wine and cheese


Friday September 28th
Session 4: Other targets in ALS (I): glia and immune system

Chairs: Stanley Appel e Marco Milanese

08.30 – 09.00 Laura Ferraiuolo

Using patient-derived astrocytes to inform precision medicine approaches

09.00 – 09.30 Stanley Appel

Suppressing neuroinflammation in ALS: cell-based therapy comes of age

09.30 – 09.45 Marta Fumagalli

AriSLA Pilot Grant Project, Call 2016
GPR17ALS – New strategies to enhance the trophic functions and remyelinating abilities of adult NG2-glia in amyotrophic lateral sclerosis via the GPR17 receptor

09.45 – 10.00 Stefano Garofalo

NK cells trigger inflammation and motoneuron death in Amyotrophic Lateral Sclerosis

10.00 – 10.15 Nora Markus

Gefitinib identified as a novel ALS therapeutic by harnessing artificial intelligence

10.15 – 10.45 Coffee Break


Session 5: Other targets in ALS (II): from brain to muscle

Chairs: Giovanni Nardo e Ludo Van Den Bosch

10.45 – 11.15 Ludo Van Den Bosch

Correction of axonal transport defects in motor neurons derived from ALS patients

11.15 – 11.45 Antonio Musarò

The physiopathologic interplay between muscle and nerve in ALS

11.45 – 12.00 Tania Zaglia

AriSLA Pilot Grant Project, Call 2016
SNOP – Optogenetic modulation of the adrenergic component of motor nerves to understand the mechanisms of muscle atrophy and neurodegeneration in ALS

12.00 – 12.15 Stefania Marcuzzo

Hyperexcitability in G93A-SOD1 neurons: multi-electrode recordings with morphological and molecular correlates

12.15 – 12.30 Tiziana Petrozziello

SOD1 prevents motor neuron death induced by the cycad neurotoxin beta-methylamino-l-alanine by modulating plasma membrane targets involved in intracellular Ca2+ homeostasis

12.30 – 12.45 Tiziana Bonifacino

Beneficial effects of metabotropic glutamate receptor type 5 down regulation on ALS progression

12.45 – 14.30 Lunch

13.30 – 14:30 Poster session: MND Meeting, discussion P28-P41

Session 6: New therapies

Chairs: Antonio Musarò and Jared Sterneckert

14.30 – 15.00 Stefania Corti

Stem cell therapy in ALS: challenges and perspectives

15.00 – 15.30 Maria Grazia Biferi

Gene therapy strategies for the treatment of motor neuron disorders

15.30 – 16.00 Alexander McCampbell

Antisense oligonucleotides as an emerging modality for treatment of motor neuron disease

16.00 – 16.15 Silvia Bonanno

FM19G11 maintains blood brain barrier structural integrity and restrains p-gp overexpression by reducing astrocytes toxicity in a human-derived in vitro cell model of familial and sporadic amyotrophic lateral sclerosis

16.15 – 16.30 Germana Cocozza

Ca2+-activated K+ channels modulate microglia affecting motor neuron survival in hSOD1G93A mice

16.30 – 17.00 Coffee Break

17.00 – 17.15 Best Poster Prizes

17.15 – 18.15 Meeting Highlights

Presented by Angelo Poletti
Piera Pasinelli
What have we learned and what will we do moving forward

Questions from community


Saturday September 29th

Workshop MND e 29°meeting AISLA

Opening remarks: Marco Bucci, Sindaco della città di Genova

08.30 – 09.30 Plenary Lecture:

Presented by Claudia Caponnetto
Jonathan D. Glass
Challenges for researchers in ALS fight

09.30 – 12.30 Parallel Sessions

Session 1 MND Workshop: Advanced tools in ALS Research

Chairs: Caterina Bendotti and Antonia Ratti

09.30 – 10.15 Nicol Birsa

Novel mouse models of ALS

10.15 – 11.00 Jared Sterneckert

Investigating ALS using induced pluripotent stem cells

11.00 – 11.30 Coffee break

11.30 – 12.15 Federica Agosta

New insights into neurodegeneration using MRI

12.15 – 13.00 Marc Emmenegger

High-throughput immune profiling in an unselected hospital cohort – epidemiology of naturally-occurring autoantibodies

Session 2 AISLA: Clinical research on ALS – Meeting with patients

Chairs: Claudia Caponnetto e Piera Pasinelli

09.30 – 10.30 Vincenzo Silani

Methodology and strategies for the development of effective clinical trials in ALS

10.30 – 11.00 Coffee break

11.00 – 12.00 Strategies to get data for research and development of effective therapies

Mario Sabatelli – National ALS BioBank
Giancarlo Logroscino – National ALS Registry

12.00 – 13.00 Edavarone: the most recent drug in Italy for ALS patients

Christian Lunetta – State of the art and patients’ point of view after one year of administration

Conclusions by Mario Melazzini
Medical research, regulatory procedures and impact on patients